Evaluation of [C-11]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation by de Vries, Erik F. J. et al.
  
 University of Groningen
Evaluation of [C-11]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat
models of inflammation
de Vries, Erik F. J.; Doorduin, Janine; Dierckx, Rudi A.; van Waarde, Aren
Published in:
Nuclear Medicine and Biology
DOI:
10.1016/j.nucmedbio.2007.07.015
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
de Vries, E. F. J., Doorduin, J., Dierckx, R. A., & van Waarde, A. (2008). Evaluation of [C-11]rofecoxib as
PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nuclear Medicine and
Biology, 35(1), 35-42. https://doi.org/10.1016/j.nucmedbio.2007.07.015
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Available online at www.sciencedirect.com
ogy 35 (2008) 35–42
www.elsevier.com/locate/nucmedbioNuclear Medicine and BiolEvaluation of [11C]rofecoxib as PET tracer for cyclooxygenase 2
overexpression in rat models of inflammation
Erik F.J. de Vries⁎, Janine Doorduin, Rudi A. Dierckx, Aren van Waarde
Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, P.O. Box 30.001,
9700 RB Groningen, The Netherlands
Received 29 June 2007; received in revised form 27 July 2007; accepted 30 July 2007Abstract
Background: Overexpression of cyclooxygenase type 2 (COX-2) is triggered by inflammatory stimuli, but it also plays a prominent role in
the initiation and progression of various diseases. This study aims to investigate [11C]rofecoxib as a positron emission tomography (PET)
tracer for COX-2 expression.
Methods: [11C]Rofecoxib was prepared by methylation of its sulphinate precursor. Regional brain distribution and specific binding of [11C]
rofecoxib in healthy rats was studied by ex vivo biodistribution and autoradiography. Regional brain distribution and PET imaging studies
were also performed on rats with severe encephalitis, caused by nasal infection with herpes simplex virus (HSV). Finally, ex vivo
biodistribution and blocking studies were carried in rats with a sterile inflammation, induced by intramuscular turpentine injection.
Results: [11C]rofecoxib brain uptake in control animals corresponded with the known distribution of COX-2. Pretreatment with NS398
significantly reduced tracer uptake in the cingulate/frontopolar cortex, whereas the reduction in hippocampus approached significance. Ex
vivo autoradiography also revealed preferential tracer uptake in hippocampus and cortical areas that could be blocked by NS398. In HSV-
infected animals, [11C]rofecoxib uptake was moderately increased in all brain regions, but it could not be blocked with indomethacin. Yet,
some PET images revealed increased tracer uptake in brain areas with microglia activation. In turpentine-injected animals, [11C]rofecoxib
uptake in inflamed muscle was not higher than in control muscle and could not be blocked with NS398. Indomethacin caused a slight
reduction in muscle uptake.
Conclusions: Despite the apparent correlation between [11C]rofecoxib uptake and COX-2 distribution in healthy rats, [11C]rofecoxib could
not unambiguously detect COX-2 overexpression in two rat models of inflammation.
© 2008 Elsevier Inc. All rights reserved.Keywords: Positron Emission Tomography; COX-2 inhibitor; NSAID; Inflammation; Microglia activation; Imaging1. Introduction
Cyclooxygenases (COX) catalyze the first two steps in
the conversion of arachidonic acid to prostaglandins and
thromboxanes. Thus far, three subtypes of COX have been
identified. The inducible subtype of the enzyme, COX-2,
plays an important role in the physiological response to
inflammatory stimuli. In addition to its role in inflammatory
disorders, COX-2 is also implicated in a variety of other
pathologies, such as cancer, cardiac and cerebral ischemia,
Alzheimer's disease and Parkinson's disease [1]. Under⁎ Corresponding author. Tel.: +31 50 3613311; fax: +31 50 3611687.
E-mail address: e.f.j.de.vries@ngmb.umcg.nl (E.F.J. de Vries).
0969-8051/$ – see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.nucmedbio.2007.07.015normal physiological conditions, COX-2 is virtually absent
in most tissues, except for the constitutive expression in the
kidneys and low expression levels in the brain. In the kidney,
COX-2 has an important function in the regulation of renal
hemodynamics and salt and water homeostasis. The function
of COX-2 in the brain is still unknown.
Inflammatory stimuli induce a strong increase in the
expression of COX-2. In the brain, the COX-2 over-
expression is predominantly located in activated microglia
and astrocytes [2]. Overexpression of COX-2 is also
observed in the process of neurodegeneration. Patients
with stroke or neurodegenerative diseases, like Alzheimer's
disease or Parkinson's disease, expressed elevated levels of
COX-2 in the affected brain areas [3]. A major problem with
studying COX-2 in the human brain is the fact that the
ig. 1. Radiosynthesis of [11C]rofecoxib via alkylation of the sulphinate
recursor with [11C]methyl iodide.
36 E.F.J. de Vries et al. / Nuclear Medicine and Biology 35 (2008) 35–42expression levels of the enzyme can only be assessed
postmortem by ex vivo laboratory analysis of tissue samples.
However, the postmortem analysis of COX-2 is complicated
by the instability of COX-2 mRNA and protein (half-life:
1–3.5 h), causing a strong dependence of the results on the
interval between analysis and the time of death [4,5]. To
overcome this problem, a noninvasive imaging method to
monitor COX-2 expression, like positron emission tomo-
graphy (PET) in combination with a suitable tracer, could
be useful. Especially in brain disorders where repetitive
tissue sampling is not possible, PET could offer the unique
opportunity to gain valuable temporal and spatial informa-
tion on the expression of COX-2 during disease progres-
sion and could thus provide more insight in the role of
COX-2 in diseases [6]. In addition, PET imaging could
allow in vivo measurement of the occupancy of COX-2
binding sites and, thus, be applied as a surrogate marker
for evaluating the efficacy of anti-inflammatory therapy
with selective COX-2 inhibitors. This information can be
of great value, because in general, it is difficult to correctly
predict the behavior of COX-inhibitors in living subjects
from in vitro data [7].
In search for a suitable PET tracer for COX-2 imaging,
several selective COX-2 inhibitors have been labeled,
including [18F]SC58125, [18F]desbromo-DuP-697, [11C]
etoricoxib, [11C]celecoxib and [11C]rofecoxib [8–12]. The
celecoxib analogue [18F]SC58125 selectively accumulated
in COX-2 expressing activated macrophages in vitro but
did not show any specific binding to COX-2 in healthy
rats or a baboon [8]. [18F]Desbromo-DuP-697 appeared to
display COX-2-related specific uptake in rats [9], but a
PET study in pigs did not show any specific binding
(personal communication). So far, no in vivo evaluation
studies of the other radiolabeled COX-2 inhibitors as PET
tracers have been published.
Rofecoxib is a highly selective COX-2 inhibitor that has
been on the market since 1999 but was withdrawn by the
manufacturer in 2004 when a clinical trial showed an
increased cardiovascular risk after daily use of 25 mg of
the drug for 36 months. Nevertheless, rofecoxib could still
be applicable as a PET tracer, since adverse effects are not
to be expected after a single injection of a tracer dose of
the drug. Moreover, the properties of rofecoxib appear to
be in accordance with those of a good PET tracer.
Rofecoxib is among the most potent and selective
inhibitors of COX-2, with the IC50 for COX-2 varying
from 18 to 44.6 nM in various cellular assays and with an
IC50 for COX-1 of N50 μM [13]. In an in vitro human
whole blood assay, the COX-1/COX-2 selectivity ratio of
rofecoxib was 35.5, which is higher than for other
commonly used COX-2 inhibitors. The lipophilicity of
rofecoxib should allow penetration of the blood–brain
barrier. Ex vivo biodistribution studies in rats revealed that
[14C]rofecoxib was distributed rapidly to most tissues
within 5 min after intravenous injection and was subse-
quently washed out [14]. The major elimination route ofF
profecoxib is by hepatic metabolism with subsequent
excretion of the metabolites into the urine. The metabolites
of rofecoxib are inactive as COX-2 inhibitors. Recently,
the labeling of rofecoxib with carbon-11 was described by
Majo et al. [10], but no evaluation of this compound has
been reported yet. In this study, we describe an alternative
labeling strategy for [11C]rofecoxib (Fig. 1) and the
evaluation of this tracer in healthy rats and two distinct
rat models of inflammation.2. Materials and methods
2.1. Materials
Solvents and reagents were obtained from commercial
suppliers and used without further purification. High-
performance liquid chromatography (HPLC) analyses and
preparative separations were performed on a Waters system,
consisting of a 515-isocratic pump, a 486-multiwavelength
UV detector operated at 274 nm and a Bicron Geiger–Müller
radioactivity detector.
2.2. Sulfinate precursor (1)
Sulfinate precursor 1 was received as a kind gift from a
company that synthesized the compound from rofecoxib
according to the following general method. Methyl sulfone
(rofecoxib, 1.0 mmol) was dissolved in 15 ml of tetra-
hydrofuran (THF) and cooled in ice. A solution of 3 M
methyl magnesium chloride (4.5 mmol) in THF was added
and the mixture stirred at ambient temperature for 1 h. When
HPLC showed remaining starting material, a further aliquot
of Grignard reagent (1.5 mmol) was added. After stirring for
another 30 min, a solution of tri-n-butylborane in THF
(6 mmol) was added, and the mixture was heated at reflux
until reaction was complete (approximately 11 h). The
mixture was poured into 250 ml of diethyl ether, and the
precipitate was filtered. The precipitate was dissolved in
THF/water (2/1) and aqueous sodium carbonate was added
until the pH was ∼12. The precipitated magnesium salts
were filtered and the filtrate evaporated to dryness. The
crude product was purified by reverse phase chromatogra-
phy (C18, 10 g). The crude product was introduced onto the
column (preequilibrated in water) in water containing ∼5%
methanol and eluted with a gradient of water rising to
methanol/water 1/4. The appropriate fractions were
37E.F.J. de Vries et al. / Nuclear Medicine and Biology 35 (2008) 35–42combined and evaporated to dryness giving the required
sodium sulfinate.
2.3. Labeling of [11C]Rofecoxib
[11C]Methane was produced via the 14N(p,α)11C nuclear
reaction by irradiating the N2+5% H2 target gas with
17 MeV protons using a Scanditronix MC17 cyclotron.
[11C]Methyl iodide was prepared from [11C]methane via
procedures that were previously described in the literature
[15]. [11C]Methyl iodide was transported by a stream of
argon (20 ml/min) into a minivial containing 1 mg sulfinate
precursor 1 in 300 μl N,N-dimethylformamide (DMF) at
room temperature. After the trapping of [11C]methyl iodide
was complete, the reaction mixture was heated at 90°C for
4 min. The reaction mixture was diluted with 1.5 ml water
and injected into a semipreparative reversed-phase Symme-
tryPrep C18 HPLC column (7 μm, 7.8×300 mm).
Purification of the product was accomplished with 35%
aqueous ethanol as the eluent at a flow rate of 3 ml/min. The
radioactive product with a retention time of 10 min was
collected (retention time of the precursor: 4min). The product
was diluted with sterile and pyrogen-free water until the
ethanol concentration was ≤10% (v/v). The identity of the
product was confirmed by coinjection with an authentic
sample on reversed-phase HPLC. The radiochemical
purity of the product was determined by analytical reversed
phase HPLC using an Alphabond C18 column (10 μm,
3.9×300 mm) and 30% acetonitrile in water as the eluent
at a flow rate of 1.5 ml/min (retention time: 8 min).
2.4. Animals
All animal studies were carried out in compliance with the
national law on animal experiments. The protocols were
approved by the animal ethics committee of the University of
Groningen. Healthy male Wistar rats were purchased from
Harlan (Horst, the Netherlands). The rats were housed in
groups under a 12-hour light–dark regimen at a constant
temperature (21°C±2°C). Standard laboratory chow (RMH-
B, Hope Farms, the Netherlands) and water were available ad
libitum. After arrival, the rats were allowed to acclimatize for
at least 7 days.
2.5. Regional brain distribution in healthy rats
Male Wistar rats (287±35 g) rats were anesthetized by
ip injection of a mixture of ketamine (25 mg/kg) and
medetomidine (0.2 mg/kg). The rats were injected into the
tail vein with 36±9 MBq [11C]rofecoxib in approximately
0.4 ml 10% aqueous ethanol. Three groups of animals
were investigated. The first group consisted of untreated
control animals (n=7). Groups 2 and 3 were iv injected
with 1.5 mg/kg of the COX-2 selective inhibitor NS398,
either 5 (n=4) or 60 min (n=5) before injection of the
tracer, respectively. After 60 min of tracer distribution, the
animals were terminated, the brains were excised, dissected
in specific regions and weighed. Tracer uptake in the braintissues was measured using a gamma counter and
expressed as standardized uptake value (SUV), which
was defined as:
SUV¼
Tissue Activity Concentration MBqg
 
*Body Weight gð Þ
Injected Dose ðMBqÞ
2.6. Phosphor storage imaging of brain slices
Sixty min after tail vein injection of [11C]rofecoxib, the
brains were excised and frozen in liquid nitrogen. The frozen
brain samples were cut into 80-μm-thick slices using a
microtome at −6 °C. Brain slices were placed on slides and
covered with a multipurpose Cyclone Storage Phosphor
Screen (Packard Instruments, Meriden, CT, USA). After
exposure for 24 h, the phosphor screens were scanned using
a Cyclone imaging system (Packard Instruments).
2.7. Herpes simplex virus encephalitis model
[11C]Rofecoxib was evaluated in the herpes simplex
virus (HSV) encephalitis model [16]. At Day 0, viral
encephalitis was induced in male Wistar rats by intranasal
application of 107 plaque-forming units of HSV type 1 in
100 μl phosphate-buffered saline (PBS) (n=5). Controls
were treated identically using PBS without virus (n=7). At
Day 6 or 7 (depending on the severity of the symptoms),
the rats were anaesthetized with a mixture of ketamine
(25 mg/kg) and medetomidine (0.2 mg/kg) and iv injected
with 54±4 MBq [11C]rofecoxib. A PET scan (microPET
Focus 220) was acquired for 60 min. Then, the animals
were terminated, and the brain was excised and dissected
into separate brain regions. Tissues were weighed, and
radioactivity was measured in a gamma counter. In
blocking experiments, the nonselective COX inhibitor
indomethacin (2.5 mg/kg) was iv injected 5 min before
injection of the tracer (n=4).
2.8. Sterile inflammation model
As an animal model of sterile inflammation, male Wistar
rats were anesthetized with a 3% isoflurane air mixture and
im injected with 0.1 ml turpentine into the thigh of the left
hind leg. The animals were divided in three groups:
untreated controls (n=4) and rats that were pretreated with
either the selective COX-2 inhibitor NS398 (n=3) or the
nonselective COX inhibitor indomethacin (n=4). After
24 h, the animals were anesthetized with 3% isoflurane/
air. In the pretreated groups, the specific binding sites were
saturated by injection of 1.5 mg/kg of COX inhibitor into
the tail vein 5 min before administration of 56±16 MBq
[11C]rofecoxib. Controls were only injected with the tracer
solution. After 60 min of tracer distribution, the animals
were terminated by extirpation of the heart while under
deep narcosis. The relevant tissues were excised, weighed
and measured for radioactivity. Tracer uptake was
expressed as SUV.
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Tracer uptake values were statistically analyzed using the
unpaired two-sided Student's t test. Differences between
groups were considered statistically significant at Pb.05.ig. 2. [11C]Rofecoxib phosphor storage images of coronal brain slices of
ealthy rats (left), showing selective tracer uptake the hippocampus and
ortical areas, and phosphor storage images of the corresponding slices of
ts that were pretreated with 1.5 mg/kg NS398 (right).3. Results
3.1. Labeling of [11C]Rofecoxib
[11C]Rofecoxib (2) was prepared by methylation of its
sulfinate precursor 1 with [11C]methyl iodide (Fig. 1). The
decay-corrected radiochemical yield was 57±9% (based on
[11C]methyl iodide, n=23). The product was isolated with a
specific activity of 14±8 GBq/μmol and a radiochemical
purity N99%. For animal studies, the product was formulated
in 10% ethanol (v/v) by dilution of the collected HPLC
fraction with sterile and pyrogen-free water. The total
synthesis time, including preparation of [11C]methyl iodide,
HPLC purification and formulation, was approximately
40 min.
3.2. [11C]rofecoxib distribution in healthy rat brain
As the brain is one of the few organs that constitutively
expresses COX-2, the regional distribution of [11C]rofecoxib
in this organ was determined. Ex vivo brain distribution
studies in untreated animals showed a heterogeneous pattern
of [11C]rofecoxib accumulation (Table 1), with an average
SUV in the total brain of 0.26±0.09. Tracer uptake in
cingulate/frontopolar cortex (+34%), hippocampus (+15%),
frontal cortex (+11%) and parietal/temporal/occipital cortex
(+10%) were significantly higher than average brain uptake,
whereas tracer uptake in cerebellum (−16%) and bulbus
olfactorius (−12%) were significantly lower (two-sided
paired Student's t test, Pb.01). To investigate whether the
accumulation of [11C]rofecoxib in the brain was due toTable 1
Distribution of radioactivity in various brain regions, 60 min after injection







Amygdala/piriform cortex 0.27±0.09 0.18±0.04 0.20±0.05
Bulbus olfactorius 0.23±0.09 0.20±0.06 0.19±0.05
Cerebellum 0.22±0.08 0.18±0.05 0.21±0.05
Cingulate/frontopolar cortex 0.35±0.11 0.18±0.04⁎ 0.19±0.04 ⁎
Entorhinal cortex 0.26±0.09 0.18±0.07 0.19±0.03
Frontal cortex 0.29±0.10 0.18±0.07 0.19±0.05
Hippocampus 0.30±0.11 0.17±0.05 0.20±0.04
Medulla 0.28±0.11 0.23±0.08 0.24±0.06
Parietal/temporal/occipital cortex 0.29±0.10 0.20±0.04 0.21±0.05
Pons 0.25±0.08 0.21±0.05 0.22±0.05
Striatum 0.25±0.08 0.19±0.07 0.21±0.06
The COX-2 inhibitor NS398 was iv injected 5 or 60 min before the tracer
was administered. Tissue uptake is expressed as SUV±S.D.




raspecific binding to COX-2, blocking experiments with the
selective COX-2 inhibitors NS398 were carried out. When
1.5 mg/kg of NS398 was administered 5 min prior to [11C]
rofecoxib injection, the tracer was more homogeneously
distributed throughout the brain than in control animals. This
NS398-induced change in distribution pattern was accom-
panied by a significant reduction (Pb.01) in [11C]rofecoxib
accumulation in cingulate/frontopolar cortex (−41%, P=.01),
whereas the reduction in hippocampus almost reached
significance (−33%, P=.06). These brain regions are known
to express significant basal levels of COX-2 in healthy
animals [17,18]. Prolongation of the interval between NS398
administration and tracer injection from 5 to 60 min did not
result in a significantly greater blockade of tracer binding,
indicating that NS398 binding to COX-2 is virtually
complete within 5 min.
To confirm the results of the ex vivo biodistribution study,
phosphor storage images were obtained from brain sections
of untreated healthy rats. Phosphor storage imaging revealed
relatively high uptake of [11C]rofecoxib in hippocampus and
cortical areas (Fig. 2). This distribution corresponds well
with the results of the ex vivo biodistribution and the
previously reported basal distribution of COX-2 in the brain
Table 2
Distribution of radioactivity in various brain regions 60 min after injection of









Amygdala/piriform cortex 0.27±0.09 0.41±0.21 0.53±0.33
Bulbus olfactorius 0.23±0.09 0.31±0.07 0.28±0.04
Cerebellum 0.22±0.08 0.25±0.04 0.23±0.03
Cingulate/frontopolar cortex 0.35±0.11 0.49±0.27 0.55±0.36
Entorhinal cortex 0.26±0.09 0.35±0.14 0.45±0.20
Frontal cortex 0.29±0.10 0.46±0.30 0.36±0.13
Hippocampus 0.30±0.11 0.48±0.30 0.66±0.41




Pons 0.25±0.08 0.29±0.05 0.25±0.04
Striatum 0.25±0.08 0.28±0.06 0.31±0.06
In a subset of infected rats, the COX inhibitor indomethacin was iv injected
5 min before the tracer was administered. Tissue uptake is expressed as
SUV±S.D.
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NS398 before injection of the tracer, the increased [11C]
rofecoxib uptake in hippocampus and cortical areas were
reduced to background levels (Fig. 2). Thus, [11C]rofecoxib
appears to bind specifically to COX-2 in specific brain
regions with highest expression levels of the enzyme.
3.3. [11C]rofecoxib distribution in the Herpes Simplex Virus
encephalitis model
Ex vivo biodistribution showed a moderate increase (5–
58%) in [11C]rofecoxib uptake in all brain regions of HSV-
infected animals, as compared to healthy controls (Table 2),
but this increase was not statistically significant for any
region (P≥.14). Administration of 2.5 mg/kg of indometha-
cin to the infected animals did not significantly reduce [11C]
rofecoxib uptake in any brain region, indicating the tracer
uptake is not saturable.
In accordance to the results of the ex vivo biodistribution
study, [11C]rofecoxib microPET images displayed low and
rather homogeneous tracer uptake in the brains of HSV-
infected animals. In some infected animals, however, slightly
higher tracer uptake was observed in the cerebellum and
brain stem region. As shown in Fig. 3, areas with increased
[11C]rofecoxib uptake corresponded with brain regions that
showed enhanced levels of activated microglia, as was
determined by [11C]PK11195 PET in a parallel study [19].
3.4. [11C]rofecoxib distribution in a sterile inflammation
rat model
Twenty-four hours after injection of turpentine in a thigh
muscle of Wistar rats, a sterile inflammation is formed that is
characterized by visible swelling of the muscle. Despite the
avid inflammatory reaction, ex vivo biodistribution showed
that [11C]rofecoxib uptake was not higher in the inflamedmuscle than in the contralateral control muscle (Fig. 4).
Administration of the selective COX-2 inhibitor NS398 did
not significantly affect tracer uptake in the inflamed muscle,
control muscle or whole blood. In contrast, treatment with
the nonselective COX inhibitor indomethacin caused a
significant reduction (Pb.05) in tracer uptake in whole blood
(−13%) and control muscle (−19%), whereas the reduction
in the inflamed muscle approached statistical significance
(−15%, P=.09).4. Discussion
In this study, we investigated the radiolabeled selective
inhibitor [11C]rofecoxib as a potential PET tracer for
imaging of COX-2 expression. The labeling of [11C]
rofecoxib and other COX-2 inhibitors was recently described
by Majo et al. [10]. They prepared [11C]rofecoxib from its
thiobutyrate ester via a two-step in situ deprotection/
methylation–oxidation procedure in 20% radiochemical
yield. Here, we described a different labeling strategy
starting from the sulphinate precursor of [11C]rofecoxib
(1). This approach yields [11C]rofecoxib in a single
methylation step and gives a radiochemical yield of almost
60%, which is more than sufficient for imaging studies in
animals and humans.
To assess the feasibility of [11C]rofecoxib as a PET tracer
for COX-2, the brain uptake of this compound was evaluated
in healthy Wistar rats, as the brain is one of the few tissues
with constitutive COX-2 expression, although expression
levels are low under normal conditions. By an ex vivo COX
peroxidase assay, we have previously confirmed that the
brain is among the organs with highest COX enzyme activity
[9]. Pharmacokinetic studies have shown that rofecoxib
rapidly penetrates the brain, resulting in cerebrospinal fluid
concentrations that are more than fivefold higher than for
other COX-2 inhibitors, like celecoxib and valdecoxib [20].
This difference was ascribed to the smaller degree of plasma
protein binding of rofecoxib. Thus, [11C]rofecoxib should
have suitable characteristics for a PET tracer for monitoring
COX-2 expression in the brain. In this study, we found low
brain uptake of [11C]rofecoxib (SUV: 0.26±0.09), suppo-
sedly reflecting the low expression levels of COX-2 in the
brain. In situ hybridization studies have demonstrated that
constitutively expressed COX-2 mRNA is not homoge-
neously distributed in the brain but predominantly located in
cortical areas and hippocampus [17,18]. In this study, we
showed that the [11C]rofecoxib distribution corresponds with
the known distribution of COX-2 mRNA. Moreover, specific
binding could be detected in brain regions with constitutive
COX-2 expression in blocking studies with the selective
COX-2 inhibitor NS398. Binding of NS398 to the active site
of the enzyme proved to be a rapid process, as blocking of
the binding site was virtually complete within 5 min.
Encouraged by these results, we also evaluated [11C]
rofecoxib in a rat model of cerebral inflammation. To this
Fig. 3. MicroPET images (0–60 min) of transversal (left), coronal (middle) and sagittal (right) cross sections of the rat brain 7 days after intranasal infection with
HSV-1. Rats were anesthetized with a mixture of ketamine (25 mg/kg) and medetomidine (0.2 mg/kg) and injected with approximately 50MBq of [11C]rofecoxib
(upper row) or [11C]PK11195 (bottom row). A coregistration of both images is displayed in the middle row. Increased uptake is observed in the area of the brain
stem and cerebellum for both tracers.
ig. 4. [11C]Rofecoxib uptake 60 min post injection in control muscle,
flamed muscle and whole blood of Wistar rats that where intramuscularly
jected with turpentine 24 h before administration of the tracer. In blocking
tudies, 1.5 mg/kg NS398 or indomethacin was iv injected 5 min before
acer injection. *Significantly different from controls, as determined by a
o-sided unpaired Student's t test (Pb.05).
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chosen because the severe inflammatory response that occurs
in this model should evoke substantial COX-2 overexpres-
sion [2]. After intranasal infection of Wistar rats with HSV,
the replicating virus migrates into the brain where it induces
intense inflammation. Consequently visible symptoms of
illness occur that increase in severity from Day 5 on [16].
These symptoms include stressed behaviour, lethargy,
impaired motor function and paralysis. Without treatment,
approximately 20% of the animals die within a week after
infection. In this model, viral infection of the brain with
HSV type 1 was confirmed by reverse transcriptase-
polymerase chain reaction analysis of the virus in brain
homogenates, immunohistochemistry for activated micro-
glial cells in brain sections and microPET imaging of
replicating herpes virus and microglial activation with [18F]
FHPG and [11C]PK11195, respectively [16,19]. Despite the
presence of severe neuroinflammation, COX-2 overexpres-






41E.F.J. de Vries et al. / Nuclear Medicine and Biology 35 (2008) 35–42model, when a group comparison between infected and
control animals was made. Still, brain areas with higher
intensity in the [11C]rofecoxib PET images than the
surrounding brain that coincided with areas of microglial
activation were observed in some animals. This could
indicate that the absolute amount of COX-2 overexpression
in this model is too low for detection or that the brain
penetration or the sensitivity of the tracer is insufficient.
Although in principle the amount of COX-2 overexpression
in HSV-infected brain could have been determined with,
e.g., an peroxidase assay, we decided to abandon this
model and to further investigate the feasibility of [11C]
rofecoxib for imaging of COX-2 expression in a completely
different model instead: a sterile inflammation in peripheral
tissue by intramuscular injection of turpentine.
Previously, we have shown that intramuscular turpen-
tine injection results in visible swelling of the inflamed
thigh muscle within 24 h due to an acute inflammatory
reaction, which can be clearly visualized by flourodeoxy-
glucose PET [21,22]. Histological examination 24 h after
turpentine injection revealed that the inflamed muscle
contains partially necrotic muscle fibers that show massive
infiltration of neutrophils. At the border of the inflamma-
tory infiltrate, macrophages and fibroblasts were present.
Activated neutrophils and macrophages are known to
express elevated levels of COX-2 [23,24]. In this model,
the tissue distribution of a tracer dose of [11C]rofecoxib
(data not shown) was in good agreement with the
distribution of [14C]rofecoxib (2 mg/kg iv) in healthy
Sprague–Dawley rats, as was described in the literature
[14]. This indicates that the PET tracer [11C]rofecoxib
displays a similar in vivo behavior as the native drug.
Nevertheless, we could not demonstrate any increased
[11C]rofecoxib uptake in the inflamed muscle relative to
the control muscle. Moreover, tracer uptake in neither
muscle could be saturated with the COX-2 inhibitor
NS398, whereas a small but significant reduction in tracer
uptake was observed after pretreatment with the non-
selective COX inhibitor indomethacin. A similar effect was
observed in whole blood. Possible explanations could be
that [11C]rofecoxib specifically binds to COX-1 in muscle,
monocytes and platelets. It has been suggested that
selective COX-2 inhibitors also show weak and reversible
binding to COX-1 [25]. The high selectivity of some
inhibitors for the COX-2 isoform is thought to be due to
their ability to irreversible bind to the active site of this
isoform. Alternatively, the effect of indomethacin may not
be due specific binding to COX-1 but to an indomethacin-
induced effect on tracer clearance, resulting in lower tracer
concentrations in tissue. A possible explanation for the
lack of specific binding could be that the enhancement in
tracer uptake as a result of increased COX-2 expression
was counteracted by the formation of edema in the muscle,
which leads to a reduction in uptake of the lipophilic tracer
per gram of tissue. Another possibility could be that the
absolute quantities of COX-2 enzyme that were induced inthe inflamed muscle were relatively small compared to the
level of nonspecific tracer uptake. Consequently, the small
portion of specific tracer uptake in the muscle would be
completely obscured. To test the latter hypothesis, we
performed a COX peroxidase assay [9] and found no
increased COX activity in the inflamed muscle (data not
shown). However, it should be noted that this peroxidase
assay is not very sensitive to small changes in COX-2
expression, as it measures the combined peroxidase
activity of COX-1 and COX-2. Nevertheless, the perox-
idase assay suggests that the up-regulation of COX-2 in
the inflamed muscle is relatively small.
As follows from the above, [11C]rofecoxib was not able to
detect any inflammation-induced COX-2 overexpression in
two animal models of inflammation, despite the fact that
rofecoxib is amongst the most potent and selective COX-2
inhibitors currently available. In fact, none of the radi-
olabeled COX-2 ligands that have been reported in the
literature so far, was able to unambiguously demonstrate
specific uptake in a model of inflammation. However, it is
still a matter of debate whether this lack of success of labeled
COX-2 inhibitors is due to shortcomings of the tracers
themselves or the result of inadequate animal models that are
used for their evaluation. It has unequivocally been
demonstrated that COX-2 expression is up-regulated
during inflammation, but absolute measures of the COX-
2 expression in inflamed tissue are hard to find, as up-
regulation of COX-2 expression is generally presented as a
relative value with respect to the control situation.
Consequently, a potential pitfall could be that, relative to
the control situation, COX-2 expression is highly up-
regulated in a specific animal model, but the absolute
concentration is still too low to be detected by PET,
because of extremely low basal expression of the enzyme.
Therefore, validated animal models with quantitative data
on COX-2 expression are urgently awaited.5. Conclusion
COX-2 plays an important role in many physiological
processes, and overexpression of this enzyme is observed
in a variety of diseases. Therefore, a suitable PET tracer
for COX-2 could be a useful tool for mechanistic studies,
diagnosis and therapy evaluation. The results of this
study show that [11C]rofecoxib uptake in normal brain
appears to reflect basal COX-2 expression. However,
[11C]rofecoxib could not detect inflammation-induced
COX-2 overexpression in two distinct rat models of
inflammation, despite the fact that severe inflammation
was induced in both models. Thus, either the absolute
amounts of COX-2 protein that are expressed during
inflammation are too low for detection, which would
make COX-2 an unsuitable target for imaging, or the
sensitivity of [11C]rofecoxib is insufficient for imaging of
COX-2 overexpression after an inflammatory response. In
42 E.F.J. de Vries et al. / Nuclear Medicine and Biology 35 (2008) 35–42the latter case, a labeled COX-2 inhibitor with sub-
nanomolar affinity may be required.
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